查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830988

荷尔蒙替代疗法市场

Hormone Replacement Therapy Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

荷尔蒙替代疗法市场预测为利害关係人提供了製定成长策略的洞见。预计该市场规模将从2024年的98.5亿美元增加至2031年的148.2亿美元，2025年至2031年的复合年增长率（CAGR）预计为7.3%。受荷尔蒙失调发病率上升、人们对荷尔蒙缺乏症认识的提高以及HRT配方的进步等因素的影响，全球对荷尔蒙替代疗法 (HRT) 的需求持续增长。生物同质性荷尔蒙替代疗法 (BHRT) 因其公认的安全性和有效性，正逐渐取代合成荷尔蒙。 BHRT源自天然，被认为能够与人体产生的荷尔蒙高度相似。

製药公司正致力于研发创新的荷尔蒙疗法配方，包括透皮贴片、凝胶、乳霜和皮下植入剂，以提高患者的便利性、依从性和安全性。这一趋势正在推动荷尔蒙替代疗法市场的成长。 2023年8月，美国食品药物管理局 (FDA) 批准了ANI Pharmaceuticals公司0.1%雌二醇凝胶的简化新药申请。参考药物Divigel是一种雌激素疗法，用于缓解与更年期相关的中度至重度血管舒缩症状。 Divigel的仿製药为0.1%雌二醇凝胶。

成长动力：广泛的应用推动荷尔蒙替代疗法市场成长。荷尔蒙替代疗法用于缓解更年期症状、治疗生长激素缺乏症等，显着影响着人们的生活。数百万女性使用荷尔蒙替代疗法 (HRT)，且通常持续较长时间。 HRT 有助于预防骨质疏鬆症，并透过多种方式提高生活品质。根据俄勒冈健康与科学大学的数据，生长激素缺乏症 (GHD) 相对罕见，在美国约有 5 万名成年人和约 4,000 至 6,000 名儿童患有此病。因此，随着荷尔蒙紊乱盛行率的上升，荷尔蒙替代疗法的普及率不断提高，推动了荷尔蒙替代疗法市场的成长。

限制因素：高昂的药物成本阻碍荷尔蒙替代疗法市场的成长。 HRT 产品的价格尤其高昂。例如，根据更年期中心的报告，口服荷尔蒙替代疗法处方的每月费用在 130 美元至 240 美元之间（相当于每年 1,560 美元至 2,440 美元）。这些高昂的费用阻碍了这些产品的常规使用，从而抑制了荷尔蒙替代疗法市场的成长。

策略洞察报告细分和范围：透过检查以下细分来分析荷尔蒙替代疗法市场：治疗、应用、给药途径和最终用户。

根据治疗方法，荷尔蒙替代疗法市场分为雌激素替代疗法、生长激素替代疗法、甲状腺激素替代疗法、睪固酮替代疗法和其他疗法。雌激素替代疗法在2023年占据了最大的市场。

荷尔蒙替代疗法市场按应用分类，包括更年期、生长激素 (GH) 缺乏症、甲状腺功能减退症、性腺功能减退症等。更年期疗法在 2023 年占据荷尔蒙替代疗法市场的最大份额，预计在预测期内将呈现最高的复合年增长率。

区域分析：从区域来看，荷尔蒙替代疗法市场报告涵盖北美、欧洲、亚太地区、南美和中美以及中东和非洲。 2023 年，北美占据了主导市场份额。先进技术的日益普及、荷尔蒙失调盛行率的上升、新产品的早期采用以及主要市场参与者的存在，共同推动了北美荷尔蒙替代疗法市场规模的不断增长。 2023 年 6 月，辉瑞公司和 OPKO Health Inc. 宣布，美国食品药物管理局 (FDA) 批准了 NGENLA (somatrogon-ghla)，这是一种每週使用一次的人类生长激素类似物，用于治疗因内源性生长激素分泌不足导致生长障碍的三岁及以上儿科患者。

此外，在预测期内，对提供优质个人化医疗服务及强化医疗保健解决方案的重视预计将为荷尔蒙替代疗法市场创造巨大机会。 2023年5月，首家全国性整合及功能医学提供者网路Forum Health, LLC收购了德州最大的荷尔蒙替代诊所网路之一Hormones by Design。

荷尔蒙替代疗法市场报告范围行业发展和未来机会：正如公司新闻稿所报导的，激素替代疗法市场主要参与者的关键策略发展包括：

2024年1月，丹麦Ascendis Pharma A/S公司与Vector Pharma FZCO（简称Vector）签署了一项独家经销协议，授权其在海湾合作委员会（GCC）国家（包括沙乌地阿拉伯、阿联酋、科威特、阿曼、卡达和巴林）销售Yorvipath和Skytrofa。根据该协议，Vector将利用其销售和市场专长，为GCC国家的患者提供用于治疗成人甲状旁腺功能减退症的Yorvipath和用于治疗儿童生长激素缺乏症（GHD）的Skytrofa。竞争格局与重点公司：荷尔蒙替代疗法市场报告中介绍的知名公司包括阿斯特捷利康、辉瑞公司、诺华公司、雅培、Tolmar公司、Par Pharmaceutical、Mayne Pharma Group Limited、诺和诺德公司、礼来公司和Noven Pharmaceuticals, Inc.。这些公司专注于开发新技术、改进现有产品并扩大其地理覆盖范围，以满足全球日益增长的消费者需求。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：荷尔蒙替代疗法市场格局

  • 概述
  • PEST分析

第五章：荷尔蒙替代疗法市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：荷尔蒙替代疗法市场－全球市场分析

  • 荷尔蒙替代疗法（HRT）-全球市场概览
  • 荷尔蒙替代疗法 (HRT) - 全球市场及 2031 年预测

第七章：荷尔蒙替代疗法市场-收入分析-依产品分类，2021-2031

  • 概述
  • 雌激素替代疗法
  • 人类生长激素（HGH）替代疗法
  • 甲状腺替代疗法
  • 睾酮替代疗法
  • 其他的

第 8 章：荷尔蒙替代疗法市场 - 收入分析 - 按给药途径，2021-2031 年

  • 概述
  • 口服
  • 肠外
  • 透皮

第九章：荷尔蒙替代疗法市场-收入分析-按疾病适应症，2021-2031

  • 概述
  • 停经
  • 甲状腺功能低下症
  • 性腺功能低下
  • 生长激素缺乏症
  • 其他的

第 10 章：荷尔蒙替代疗法市场 - 收入分析 - 按配销通路，2021-2031 年

  • 概述
  • 医院
  • 专科诊所
  • 其他的

第 11 章：荷尔蒙替代疗法市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 13 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 14 章：荷尔蒙替代疗法市场 - 主要公司简介

  • Astrazeneca
  • Pfizer Inc.
  • Novartis AG
  • Abbott
  • Tolmar Inc
  • Par Pharmaceutical
  • Mayne Pharma Group Limited
  • Novo Nordisk A/S
  • Eli Lily And Company
  • Noven Pharmaceuticals, Inc.

第 15 章：附录

简介目录
Product Code: TIPRE00003836

The forecast for the hormone replacement therapy market provides stakeholders with insights to shape their growth strategies. The market is anticipated to expand from US$ 9.85 billion in 2024 to US$ 14.82 billion by 2031, with an estimated CAGR of 7.3% from 2025 to 2031.The global demand for hormone replacement therapy (HRT) is consistently increasing due to factors such as the rising incidence of hormonal disorders, heightened awareness of hormone deficiencies, and advancements in HRT formulations. Bioidentical hormone replacement therapy (BHRT) is gaining popularity over synthetic hormones due to its perceived safety and effectiveness. BHRT, derived from natural sources, is believed to closely mimic the hormones produced by the body.

Pharmaceutical companies are focusing on creating innovative hormone therapy formulations, including transdermal patches, gels, creams, and subcutaneous implants, to enhance patient convenience, adherence, and safety. This trend is driving the growth of the hormone replacement therapy market. In August 2023, the Food and Drug Administration (FDA) approved ANI Pharmaceuticals' abbreviated new drug application for a 0.1% estradiol gel. The reference medication, Divigel, is an estrogen hormone therapy used to alleviate moderate to severe vasomotor symptoms associated with menopause. The generic version of Divigel is estradiol gel, 0.1%.

Growth Drivers:Extensive Applications Fuel Hormone Replacement Therapy Market Growth

Hormone replacement therapy is utilized to alleviate menopause symptoms, treat growth hormone deficiency, and more, significantly impacting individuals' lives. Millions of women utilize HRT, often for extended periods. HRT can help prevent osteoporosis and enhance quality of life in various ways. According to Oregon Health & Science University, growth hormone deficiency (GHD) is relatively rare, affecting about 50,000 adults in the US and approximately one in 4,000 to 6,000 children. Therefore, the increasing adoption of therapy alongside the rising prevalence of hormonal disorders is propelling the growth of the hormone replacement therapy market.

Restraint:High Medication Costs Impede Hormone Replacement Therapy Market Growth

The prices of HRT products are notably high. For example, the monthly cost of oral hormone replacement therapy prescriptions ranges from US$ 130 to US$ 240 (equating to US$ 1,560 to US$ 2,440 annually), as reported by The Menopause Center. These high costs hinder the regular use of these products, thus restraining the growth of the hormone replacement therapy market.

Strategic Insights

Report Segmentation and Scope:The analysis of the hormone replacement therapy market has been conducted by examining the following segments: therapy, application, route of administration, and end user.

By therapy, the hormone replacement therapy market is divided into estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, testosterone replacement, and others. The estrogen hormone replacement segment accounted for the largest market share in 2023.

The hormone replacement therapy market, categorized by application, includes menopause, growth hormone (GH) deficiency, hypothyroidism, hypogonadism, and others. The menopause segment held the largest share of the hormone replacement therapy market in 2023 and is expected to exhibit the highest CAGR during the forecast period.

Regional Analysis:Regionally, the hormone replacement therapy market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America dominated the market share. The increasing adoption of advanced technologies, the rising prevalence of hormonal disorders, early adoption of new products, and the presence of key market players contribute to the growing hormone replacement therapy market size in North America. In June 2023, the US Food and Drug Administration (FDA) approved NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog, for treating pediatric patients aged three years and older with growth failure due to insufficient endogenous growth hormone secretion, as announced by Pfizer Inc. and OPKO Health Inc.

Moreover, a heightened focus on providing access to quality personalized care and enhancing healthcare solutions is expected to create significant opportunities for the hormone replacement therapy market during the forecast period. In May 2023, Forum Health, LLC, the first national network of integrative and functional medicine providers, acquired Hormones by Design, one of the largest networks of hormone replacement clinics in Texas.

Hormone Replacement Therapy Market Report Scope

Industry Developments and Future Opportunities:Key strategic developments by leading players in the hormone replacement therapy market, as reported in company press releases, include:

In January 2024, Ascendis Pharma A/S of Denmark and Vector Pharma FZCO (Vector) entered into an exclusive distribution agreement for the commercialization of Yorvipath and Skytrofa in the Gulf Cooperation Council (GCC) countries, including Saudi Arabia, the UAE, Kuwait, Oman, Qatar, and Bahrain. Under this agreement, Vector will leverage its sales and marketing expertise to provide patients in the GCC with Yorvipath for adult hypoparathyroidism and Skytrofa for pediatric growth hormone deficiency (GHD).

Competitive Landscape and Key Companies:Prominent companies profiled in the hormone replacement therapy market report include Astrazeneca, Pfizer Inc., Novartis AG, Abbott, Tolmar Inc., Par Pharmaceutical, Mayne Pharma Group Limited, Novo Nordisk A/S, Eli Lilly and Company, and Noven Pharmaceuticals, Inc. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the increasing consumer demand globally.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hormone Replacement Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Hormone Replacement Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Hormone Replacement Therapy Market - Global Market Analysis

  • 6.1 Hormone Replacement Therapy (HRT) - Global Market Overview
  • 6.2 Hormone Replacement Therapy (HRT) - Global Market and Forecast to 2031

7. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Products, 2021-2031

  • 7.1 Overview
  • 7.2 Estrogen Replacement Therapy
  • 7.3 Human Growth Hormone (HGH) Replacement Therapy
  • 7.4 Thyroid Replacement Therapy
  • 7.5 Testosterone Replacement Therapy
  • 7.6 Others

8. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Route Of Administration, 2021-2031

  • 8.1 Overview
  • 8.2 Oral
  • 8.3 Parenteral
  • 8.4 Transdermal

9. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 9.1 Overview
  • 9.2 Menopause
  • 9.3 Hypothyroidism
  • 9.4 Hypogonadism
  • 9.5 Growth Hormone Deficiency
  • 9.6 Others

10. Hormone Replacement Therapy Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Others

11. Hormone Replacement Therapy Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Hormone Replacement Therapy Market Overview
    • 11.1.2 North America Hormone Replacement Therapy Market Revenue and Forecasts to 2031
    • 11.1.3 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Products
    • 11.1.4 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Route Of Administration
    • 11.1.5 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Disease Indication
    • 11.1.6 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.7 North America Hormone Replacement Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Hormone Replacement Therapy Market
        • 11.1.7.1.1 United States Hormone Replacement Therapy Market, by Products
        • 11.1.7.1.2 United States Hormone Replacement Therapy Market, by Route Of Administration
        • 11.1.7.1.3 United States Hormone Replacement Therapy Market, by Disease Indication
        • 11.1.7.1.4 United States Hormone Replacement Therapy Market, by Distribution Channel
      • 11.1.7.2 Canada Hormone Replacement Therapy Market
        • 11.1.7.2.1 Canada Hormone Replacement Therapy Market, by Products
        • 11.1.7.2.2 Canada Hormone Replacement Therapy Market, by Route Of Administration
        • 11.1.7.2.3 Canada Hormone Replacement Therapy Market, by Disease Indication
        • 11.1.7.2.4 Canada Hormone Replacement Therapy Market, by Distribution Channel
      • 11.1.7.3 Mexico Hormone Replacement Therapy Market
        • 11.1.7.3.1 Mexico Hormone Replacement Therapy Market, by Products
        • 11.1.7.3.2 Mexico Hormone Replacement Therapy Market, by Route Of Administration
        • 11.1.7.3.3 Mexico Hormone Replacement Therapy Market, by Disease Indication
        • 11.1.7.3.4 Mexico Hormone Replacement Therapy Market, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Hormone Replacement Therapy Market - Key Company Profiles

  • 14.1 Astrazeneca
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc.
  • 14.3 Novartis AG
  • 14.4 Abbott
  • 14.5 Tolmar Inc
  • 14.6 Par Pharmaceutical
  • 14.7 Mayne Pharma Group Limited
  • 14.8 Novo Nordisk A/S
  • 14.9 Eli Lily And Company
  • 14.10 Noven Pharmaceuticals, Inc.

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud